A midsize flight from Nasdaq to the Big Board
Article Abstract:
Wilmington Trust Corp (Wilmington, DE) has followed other Philadelphia-area companies in listing its stock on the New York Stock Exchange. Wilmington Trust had been listed on Nasdaq since the all-electronic exchange opened in 1970. Eighty six Philadelphia-area companies are now listed on NYSE, and of those, over 20% moved to NYSE from Nasdaq in the 1990s. Wilmington Trust Chairman Ted T. Cecala was willing to pay the extra $10,000 annual fee for a New York Stock Exchange listing, because NYSE employs specialists to prevent wild stock swings.
Publication Name: Philadelphia Inquirer (PA)
Subject: Business, regional
ISSN: 0885-6613
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Citizens lines up its latest bank deal
Article Abstract:
The Rhode Island Company, Citizens Bank that is working to establish as a major player in the Philadelphia market, has agreed to buy Roxborough-Manayunk Bank and its 15 branches for $136 million. The smaller bank has about $550 million in deposits and $320 million in loans at its branches, which are concentrated along the western edge of Philadelphia.
Publication Name: Philadelphia Inquirer (PA)
Subject: Business, regional
ISSN: 0885-6613
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Rite Aid is given $1 billion boost from lenders. Rite Aid is selling its PCS business. Rite Aid's loss grew during its 2d quarter
- Abstracts: Two will say no to PhilEx merger. Philex board accepts most of sale offer. PhilEx to settle class-action suit for $2.8 million
- Abstracts: Deal set to assist Internet trading. VerticalNet's CEO quits after 5 months. SunGard to buy part of Bridge
- Abstracts: PGW to seek new loan from city; the utility says it will need $45 million to pay workers and stock up on natural gas for the winter season
- Abstracts: Troubles will delay successor to Claritin. U.S. GlaxoSmithKline unit is losing one copresident. Fen-phen costs rise for drug company